Mechanisms of diabetic nephropathy - Old buddies and newcomers part 1

Experimental and Clinical Endocrinology and Diabetes

Volumn 118, Issue 9, 2010, Pages 571-576

  Nawroth, P P ^a   Isermann, B ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

diabetes; disease mechanism; nephropathy

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ANGIOTENSIN ANTAGONIST; BRADYKININ; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROTEIN KINASE C; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RUBOXISTAURIN; TRANSFORMING GROWTH FACTOR BETA;

DIABETIC NEPHROPATHY; DISEASE COURSE; ENZYME INHIBITION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HUMAN; KIDNEY FUNCTION; MICROALBUMINURIA; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

ANIMALS; DIABETIC RETINOPATHY; ENDOCRINOLOGY; GENETIC ASSOCIATION STUDIES; HUMANS; MODELS, BIOLOGICAL; MOLECULAR TARGETED THERAPY; RESEARCH; SIGNAL TRANSDUCTION;

EID: 77958114639     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0030-1255051     Document Type: Review

References (56)

1. Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes 2003 52 1036-1040
2. Jerums G, Premaratne E, Panagiotopoulos S, et al. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008 82 S30-S37
3. Mauer M, Zinman B, Gardiner R, et al. Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009 361 40-51
4. Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003 348 2285-2293
5. Hovind P, Tarnow L, Parving HH. Remission and regression of diabetic nephropathy. Curr Hypertens Rep 2004 6 377-382
6. Gaede P, Tarnow L, Vedel P, et al. Remission to normoalbuminuria during multifactorial treatment preserves kidney function in patients with type 2 diabetes and microalbuminuria. Nephrol Dial Transplant 2004 19 2784-2788
7. Holman RR, Paul SK, Bethel MA, et al. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 2008 359 1565-1576
8. Fioretto P, Caramori ML, Mauer M. The kidney in diabetes: dynamic pathways of injury and repair. The Camillo Golgi Lecture 2007. Diabetologia 2008 51 1347-1355
9. Dummy EDIC. Sustained effect of intensive treatment of type 1 diabetes mellitus on development and progression of diabetic nephropathy: the Epidemiology of Diabetes Interventions and Complications (EDIC) study. JAMA 2003 290 2159-2167
10. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008 359 1577-1589
11. Chen HQ, Veluthakal R, Palanivel R, et al. GTP-binding protein-independent potentiation by mastoparan of IL-1beta-induced nitric oxide release from insulin-secreting HIT-T15 cells. Apoptosis 2004 9 145-148
12. Ihnat MA, Thorpe JE, Kamat CD, et al. Reactive oxygen species mediate a cellular memory of high glucose stress signalling. Diabetologia 2007 50 1523-1531
13. El-Osta A, Brasacchio D, Yao D, et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 2008 205 2409-2417
14. Toyoda M, Najafian B, Kim Y, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007 56 2155-2160
15. Fioretto P, Steffes MW, Mauer M. Glomerular structure in nonproteinuric IDDM patients with various levels of albuminuria. Diabetes 1994 43 1358-1364
16. Caramori ML, Kim Y, Huang C, et al. Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. Diabetes 2002 51 506-513
17. Pagtalunan ME, Miller PL, Jumping-Eagle S, et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997 99 342-348
18. Langham RG, Kelly DJ, Cox AJ, et al. Proteinuria and the expression of the podocyte slit diaphragm protein, nephrin, in diabetic nephropathy: effects of angiotensin converting enzyme inhibition. Diabetologia 2002 45 1572-1576
19. Wharram BL, Goyal M, Wiggins JE, et al. Podocyte depletion causes glomerulosclerosis: diphtheria toxin-induced podocyte depletion in rats expressing human diphtheria toxin receptor transgene. J Am Soc Nephrol 2005 16 2941-2952
20. Kalluri R. Proteinuria with and without renal glomerular podocyte effacement. J Am Soc Nephrol 2006 17 2383-2389
21. Jarad G, Miner JH. Albuminuria, wherefore art thou? J Am Soc Nephrol 2009 20 455-457
22. Russo LM, Sandoval RM, Campos SB, et al. Impaired tubular uptake explains albuminuria in early diabetic nephropathy. J Am Soc Nephrol 2009 20 489-494
23. Lindenmeyer MT, Kretzler M, Boucherot A, et al. Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy. J Am Soc Nephrol 2007 18 1765-1776
24. Sato W, Kosugi T, Zhang L, et al. The pivotal role of VEGF on glomerular macrophage infiltration in advanced diabetic nephropathy. Lab Invest 2008 88 949-961
25. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 2001 414 813-820
26. Hammes HP, Du X, Edelstein D, et al. Benfotiamine blocks 3 major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003 9 294-299
27. Asaba K, Tojo A, Onozato ML, et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005 67 1890-1898
28. Thallas-Bonke V, Thorpe SR, Coughlan MT, et al. Inhibition of NADPH oxidase prevents advanced glycation end product-mediated damage in diabetic nephropathy through a protein kinase C-alpha-dependent pathway. Diabetes 2008 57 460-469
29. Fujii J, Myint T, Okado A, et al. Oxidative stress caused by glycation of Cu,Zn-superoxide dismutase and its effects on intracellular components. Nephrol Dial Transplant 1996 11 34-40
30. Bierhaus A, Humpert PM, Morcos M, et al. Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 2005 83 876-886
31. Forbes JM, Fukami K, Cooper ME. Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007 115 69-84
32. Shankar A, Klein R, Klein BE, et al. Association between glycosylated hemoglobin level and 16-year incidence of chronic kidney disease in type 1 diabetes. Exp Clin Endocrinol Diabetes 2007 115 203-206
33. Coughlan MT, Thorburn DR, Penfold SA, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009 20 742-752
34. Bohlender JM, Franke S, Stein G, et al. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005 289 F645-F659
35. Wendt TM, Tanji N, Guo J, et al. RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy. Am J Pathol 2003 162 1123-1137
36. Muller-Krebs S, Kihm LP, Zeier B, et al. Renal toxicity mediated by glucose degradation products in a rat model of advanced renal failure. Eur J Clin Invest 2008 38 296-305
37. Stopper H, Schinzel R, Sebekova K, et al. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett 2003 190 151-156
38. Coughlan MT, Thorburn DR, Penfold SA, et al. RAGE-induced cytosolic ROS promote mitochondrial superoxide generation in diabetes. J Am Soc Nephrol 2009 20 742-752
39. Usui HK, Shikata K, Sasaki M, et al. Macrophage scavenger receptor-a-deficient mice are resistant against diabetic nephropathy through amelioration of microinflammation. Diabetes 2007 56 363-372
40. Morcos M, Sayed AA, Bierhaus A, et al. Activation of tubular epithelial cells in diabetic nephropathy. Diabetes 2002 51 3532-3544
41. Morcos M, Schlotterer A, Sayed AA, et al. Rosiglitazone reduces angiotensin II and advanced glycation end product-dependent sustained nuclear factor-kappaB activation in cultured human proximal tubular epithelial cells. Horm Metab Res 2008 40 752-759
42. Oldfield MD, Bach LA, Forbes JM, et al. Advanced glycation end products cause epithelial-myofibroblast transdifferentiation via the receptor for advanced glycation end products (RAGE). J Clin Invest 2001 108 1853-1863
43. Lu YL, Jimbu YM, Chen Y, et al. The effects of rosiglitazione on renal artery endothelium in diabetic rats. Exp Clin Endocrinol Diabetes 2008 116 537-540
44. Miyata T, Van Ypersele De SC, Ueda Y, et al. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J Am Soc Nephrol 2002 13 2478-2487
45. Sun HL, Sun L, Li YY, et al. ACE-inhibitor suppresses the apoptosis induced by endoplasmic reticulum stress in renal tubular in experimental diabetic rats. Exp Clin Endocrinol Diabetes 2009 117 336-344
46. Kakoki M, Takahashi N, Jennette JC, et al. Diabetic nephropathy is markedly enhanced in mice lacking the bradykinin B2 receptor. Proc Natl Acad Sci USA 2004 101 13302-13305
47. Allard J, Buleon M, Cellier E, et al. ACE inhibitor reduces growth factor receptor expression and signaling but also albuminuria through B2-kinin glomerular receptor activation in diabetic rats. Am J Physiol Renal Physiol 2007 293 F1083-F1092
48. Bodin S, Chollet C, Goncalves-Mendes N, et al. Kallikrein protects against microalbuminuria in experimental type I diabetes. Kidney Int 2009 76 395-403
49. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008 372 547-553
50. Ishii H, Jirousek MR, Koya D, et al. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 1996 272 728-731
51. Meier M, Menne J, Haller H. Targeting the protein kinase C family in the diabetic kidney: lessons from analysis of mutant mice. Diabetologia 2009 52 765-775
52. Meier M, Menne J, Park JK, et al. Deletion of protein kinase C-epsilon signaling pathway induces glomerulosclerosis and tubulointerstitial fibrosis in vivo. J Am Soc Nephrol 2007 18 1190-1198
53. Sharma K, Jin Y, Guo J, et al. Neutralization of TGF-beta by anti-TGF-beta antibody attenuates kidney hypertrophy and the enhanced extracellular matrix gene expression in STZ-induced diabetic mice. Diabetes 1996 45 522-530
54. Ziyadeh FN, Hoffman BB, Han DC, et al. Long-term prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice. Proc Natl Acad Sci USA 2000 97 8015-8020
55. Ohtomo S, Izuhara Y, Takizawa S, et al. Thiazolidinediones provide better renoprotection than insulin in an obese, hypertensive type II diabetic rat model. Kidney Int 2007 72 1512-1519
56. Caramori ML, Fioretto P, Mauer M. Enhancing the predictive value of urinary albumin for diabetic nephropathy. J Am Soc Nephrol 2006 17 339-352